Piper Sandler analyst Allison Bratzel maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

FIRST IN PI: With Donald Trump cruising to a second term in the White House in part by eschewing traditional media outlets in favor of the podcast circuit, a progressive public affairs firm is warning ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...

Akebia Therapeutics ( (AKBA) ) has released its Q3 earnings. Here is a breakdown of the information Akebia Therapeutics presented to its ...

Akebia Therapeutics, Inc. (NASDAQ: AKBA) 于2024年11月7日讨论了其第三季度财务业绩，重点关注其贫血药物Vafseo（vadadustat）将于2025年1月在美国市场上市的准备工作。尽管总收入从去年同期的4200万美元降至3740万美元，但公司对Vafseo在透析和非透析慢性肾病患者群体中的潜力持乐观态度。 Akebia已经获得了报销协议，并正在积极与 ...

英为财情Investing.com - Akebia Therapeutics (NASDAQ: AKBA)星期四发布了第三季度的财报，数据显示，公司营收逊于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.100，总营收为$37.43M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$44.5M，每股收益为$-0.06 ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $20 million in its third quarter. The Cambridge, Massachusetts-based company said it had ...

Akebia (NASDAQ:AKBA) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open. The ...

CAMBRIDGE, Mass. - Akebia Therapeutics, Inc. (NASDAQ: NASDAQ:AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced a multi-year commercial contract with a top kidney ...